Shots: AstraZeneca has completed its agreement with Allergan to recover the global rights to brazikumab (formerly MEDI2070). Both the companies have terminated their 2016 agreement and all rights to brazikumab, now returned to AstraZeneca Allergan to fund up to an agreed amount, estimated to be the total costs expected to be incurred by AstraZeneca until […]Read More
Shots: Allergan will divest its brazikumab to AstraZeneca including its global development and commercialization rights while Nestle to acquire complete ownership of Zenpep and will be acquiring Viokace as a part of the same transaction The divestiture of two therapies is in conjunction with the ongoing US FTC’s and EC’s approval. The transactions are expected […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
